Related Experiment Video
Updated: Apr 30, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Practical aspects of risk assessment in gastrointestinal stromal tumors
1Division of Medical Oncology, Fred Hutchinson Cancer Research Center, University of Washington, 825 Eastlake Avenue East, G-3630, Seattle, WA, 98109-1023, USA, rjones@seattlecca.org.
Introduction:
Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors of the gastrointestinal tract, which are characterized in the majority of cases by activating mutations in KIT and platelet-derived growth factor receptor alpha (PDGFRA). The introduction of tyrosine kinase inhibitors has revolutionized the management of patients with metastatic GIST. However, complete surgical resection remains the mainstay of management for those with localized disease. Recently, three large trials have confirmed the benefit of adjuvant imatinib therapy in patients who were at high risk of recurrence following complete resection. In this setting, it is critical that oncologists understand the various GIST risk assessment criteria and be able to apply these methods to accurately assess the risk of recurrence and the need for adjuvant imatinib therapy.
Purpose:
The aim of this review is to outline the risk stratification systems currently available to oncologists who are treating patients with GIST, so they can be optimally applied for clinical decision-making.
Insights
Gastrointestinal stromal tumors (GISTs) require accurate risk assessment for adjuvant imatinib therapy. This review details GIST risk stratification systems to guide oncologists in managing localized disease and preventing recurrence.
Area of Science:
- Oncology
- Gastroenterology
- Surgical Oncology
Background:
- Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms.
- Activating mutations in KIT and PDGFRA are common in GIST.
- Tyrosine kinase inhibitors have improved metastatic GIST management, but surgery is key for localized disease.
Purpose of the Study:
- To review GIST risk stratification systems for clinical decision-making.
- To aid oncologists in assessing recurrence risk and adjuvant therapy needs.
Main Methods:
- Review of current GIST risk assessment criteria.
- Analysis of data from recent clinical trials on adjuvant imatinib therapy.
Main Results:
- Adjuvant imatinib therapy benefits high-risk GIST patients post-resection.
- Accurate risk assessment is crucial for treatment planning.
Conclusions:
- Understanding and applying GIST risk stratification is essential.
- Optimizing adjuvant imatinib use improves patient outcomes.
